uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Appropriate prophylaxis with restrictive palivizumab regimen in preterm children in Sweden
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Women's and Children's Health. (Barnendokrinologisk forskning/Tuvemo)
Show others and affiliations
2004 (English)In: Acta Paediatrica, ISSN 0803-5253, E-ISSN 1651-2227, Vol. 93, no 11, 1470-1473 p.Article in journal (Other academic) Published
Abstract [en]

AIM: Palivizumab (Synagis) was registered in Sweden in 1999 for prophylaxis against respiratory syncytial virus (RSV) in premature infants. The high costs and the limited knowledge of the efficacy of this substance have led to debate about how and when it should be used. National guidelines for the use of palivizumab in Sweden were constructed in the year 2000. The aim of this study was to evaluate the guidelines.

METHODS: A nation-wide prospective study was conducted during the two RSV seasons of the years 2000-2002. The paediatric departments in Sweden reported the use of palivizumab, the indication for its use, and the number of infants born preterm before 36 wk of gestation and less than 2 y old who were admitted to hospital for RSV infection.

RESULTS: During the two seasons, 218 (3.8%) children who were born before 36 wk of gestation, and 97 (5.4%) who were born before 33 wk, were hospitalized because of RSV infection. Five children were treated with mechanical ventilation. No death caused by RSV was reported. A total of 390 children were treated with palivizumab, and 16 (4.1%) of those who received prophylactic treatment were admitted to hospital with RSV infection.

CONCLUSION: We consider the comparatively restrictive Swedish recommendations to be safe and recommend that palivizumab should also be used very restrictively in the future. In our opinion, palivizumab in preterm children could be recommended only for those with chronic lung disease younger than 1 y of age, and with active treatment for their disease.

Place, publisher, year, edition, pages
2004. Vol. 93, no 11, 1470-1473 p.
Keyword [en]
National guidelines, palivizumab, prophylaxis, respiratory syncytial virus
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-67373DOI: 10.1111/j.1651-2227.2004.tb02631.xPubMedID: 15513574OAI: oai:DiVA.org:uu-67373DiVA: diva2:95284
Available from: 2004-11-22 Created: 2004-11-22 Last updated: 2010-10-14Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMedhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=15513574&dopt=Citation

Search in DiVA

By author/editor
Ewald, Uwe
By organisation
Department of Women's and Children's Health
In the same journal
Acta Paediatrica
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 203 hits
ReferencesLink to record
Permanent link

Direct link